Medivation, Inc.

Medivation, Inc.

Medivation, Inc. was founded in 2003 and is based in San Francisco, California. Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, which is in pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, and is in Phase 2 clinical trial in patients with mild-to-moderate Huntington's disease; and MDV3100, a Phase 1-2 clinical trial product in patients with castration-resistant prostate cancer. The company has a collaboration agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases, as well as an agreement to develop and commercialize MDV3100, an investigational drug for the treatment of prostate cancer.

Contact Details

Office Address

Medivation, Inc.
201 Spear Street, 3rd Floor
San Francisco, CA, USA 94105
Phone: (415) 543-3470
Fax: (415) 543-3411

Executives

Chief Exec. Officer, Pres and Exec. Director

Dr. David Hung

Chief Financial Officer

Mr. C. Patrick Machado

Business Reviews for Medivation, Inc.

Related Companies